ArticleBritish journal of cancer2022

No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.

Zachary Veitch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.